Bempedoic acid is under clinical development by Esperion Therapeutics and currently in Phase III for Cardiovascular Disease. According to GlobalData, Phase III drugs for Cardiovascular Disease have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Bempedoic acid’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bempedoic acid overview
Bempedoic acid (Nexletol) is a non-statin lipid lowering agent. It is formulated as film coated tablets for oral route of administration. Nexletol is indicated for the treatment of adults with hetrozygous familial hypercholestrolemia or established atherosclerotic cardiovascular disease who require additional loweing of LDL-C.
Bempedoic acid is under development for the treatment of hypercholesterolemia, atherosclerosis, hyperlipidemia, homozygous familial hypercholesterolemia (hoFH) and children (6 to 17 years of age) with heterozygous familial hypercholesterolemia, cardiovascular disease (statin intolerant adverse events) and to reduce cardiovascular risk in patients with or at high risk for atherosclerotic cardiovascular disease. The drug candidate is a small molecule, administered via oral route as a tablet. The drug candidate acts by targeting AMP (Adenosine Monophosphate) kinase.
Esperion Therapeutics overview
Esperion Therapeutics (Esperion) is a pharmaceutical company that develops and commercializes once-daily, oral and low-density lipoprotein cholesterol-lowering therapies. The company develops oral therapies to treat patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate, Bempedoic acid is an ATP-citrate lyase inhibitor is in the clinical development phase that reduces elevated LDL-C levels in patients with hypercholesterolemia. The company also provides the development of bempedoic acid in a fixed-dose combination with ezetimibe, an LDL-C lowering therapy. Esperion is headquartered in Ann Arbor, Michigan, the US.
For a complete picture of Bempedoic acid’s drug-specific PTSR and LoA scores, buy the report here.